Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Witty Succumbs To Pressure: GSK Starts Formal Search For New CEO

This article was originally published in Scrip

Executive Summary

You may also be interested in...



GSK's Vaccines Chief Slaoui To Follow Witty Out The Door

One person definitely not lining up to take over from Sir Andrew Witty when he retires from GlaxoSmithKline PLC in March 2017 is its vaccines chief and former head of R&D Dr. Moncef Slaoui. He is to retire from the company in June 2017.

What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK

The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.

Executives On The Move: NervGen Pharma, Janux Therapeutics and More

Recent executive moves in the industry include C-suite changes at NervGen Pharma and Phathom Pharmaceuticals and Clarity Pharmaceuticals. Meanwhile, new directors were appointed at Janux Therapeutics and PepGen.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC064771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel